Frontotemporal dementia: Neuropil spheroids and presynaptic terminal degeneration

Annals of Neurology

Volumn 44, Issue 1, 1998, Pages 99-109

  Zhou, L ^a   Miller, B L ^b   McDaniel, C H ^a   Kelly, L ^a   Kim, O J ^a   Miller, C A ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UCLA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TAU PROTEIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DEMENTIA; FEMALE; GLIOSIS; GLYCATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; IMMUNOREACTIVITY; MALE; NERVE CELL DEGENERATION; NEUROPATHOLOGY; NEUROPIL; PATHOGENESIS; PICK PRESENILE DEMENTIA; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN PHOSPHORYLATION; SPHEROID CELL;

ADULT; AGED; AGED, 80 AND OVER; BRAIN; CEREBRAL CORTEX; DEMENTIA; FEMALE; FRONTAL LOBE; GLIOSIS; HIPPOCAMPUS; HUMANS; LECTINS; MAGNETIC RESONANCE IMAGING; MALE; MICROSCOPY, ELECTRON; MIDDLE AGED; NEUROLOGIC EXAMINATION; NEUROPIL; ORGAN SIZE; PRESYNAPTIC TERMINALS; RETROGRADE DEGENERATION; TAU PROTEINS; TUBULIN;

EID: 0031878572     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.410440116     Document Type: Article

References (47)

1. Jackson M, Lowe J. The new neuropathology of degenerative fronto-temporal dementias. Acta Neuropathol 1996;91:127-134
2. Mann DMA, South PW, Snowden JS, Neary D. Dementia of frontal lobe type: neuropathology and immunohistochemistry. J Neurol Neurosurg Psychiatry 1993;56:605-614
3. Gustafson L, Brun A, Risberg J. Frontal lobe dementia of non-Alzheimer type. Adv Neurol 1990;51:65-71
4. Foster NL, Wilhelmson K, Sima AAF, et al. Fronto-temporal dementia and parkinsonism linked to chromosome 17: a consensus. Ann Neurol 1997;42:706-715
5. Wilhelmson KC, Lynch T, Pavlou E, et al. Localization of disinhibition-dementia-parkinsonism-amyotrophy complex to 17q 21-22. Am J Hum Genet 1994;55:1159-1165
6. Knopman DS, Mastri AR, Frey WH, et al. Dementia lacking distinctive histologic features: a common non-Alzheimer degenerative dementia. Neurology 1990;40:251-256
7. Jackson M, Lennox G, Ward L, Lowe J. Frontal dementia with MND inclusions without clinical ALS: report of eleven cases. Neuropathol Appl Neurobiol 1995;21:148-149
8. Cooper PN, Jackson M, Lennox G, et al. Tau ubiquitin, and α B-crystallin immunohistochemistry define the principal causes of degenerative fronto-temporal dementia. Arch Neurol 1995; 52:1011-1015
9. Wightman G, Anderson VER, Martin J, et al. Hippocampal and neocortical ubiquitin-immunoreactive inclusions in amyotrophic lateral sclerosis with dementia. Neurosci Lett 1992;139:269-274
10. Sima AAF, Defendini R, Keohane C, et al. The neuropathology of chromosome 17-linked dementia. Ann Neurol 1996;39: 734-743
11. Liu X, Erikson C, Brun A. Cortical synaptic changes and gliosis in normal aging, Alzheimer's disease and frontal lobe degeneration. Dementia 1996;7:128-134
12. The Lund and Manchester groups. Clinical and neuropathological criteria for frontotemporal dementia. J Neurol Neurosurg Psychiatry 1994;57:416-418
13. Mirra SS, Heyman A, McKeel D, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD), part II: standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 1991;41:479-486
14. Feany MB, Mattiace LA, Dickson DW. Neuropathologic overlap of progressive supranuclear palsy, Pick's disease and corticobasal degeneration. J Neuropathol Exp Neurol 1996;55:53-67
15. Miller CA, Rudnicka M, Hinton DR, et al. Monoclonal antibody identification of subpopulations of cerebral cortical neurons affected in Alzheimer's disease. Proc Natl Acad Sci USA 1987;84:8657-8661
16. Smith M, Rudnicka-Nawrot M, Richey PL, et al. Carbonyl-related posttranslational modification of neurofilament protein in the neurofibrillary pathology of Alzheimer's disease. J Neurochem 1995;64:2660-2666
17. Shi SR, Key ME, Kalsa KL. Antigen retrieval in formalin-fixed, paraffin-embedded tissues: an enhancement method for immunohistochemical staining based on microwave oven heating of tissue sections. J Histochem Cytochem 1991;39:741-748
18. Wang JZ, Grundke-Iqbal I, Iqbal K. Glycosylation of microtubule-associated protein tau: an abnormal post translational modification in Alzheimer's disease. Nat Med 1996;2: 871-875
19. Anderson PW, Macaulay L, Do YS, et al. Extrarenal reninsecreting tumors: insights into hypertension and ovarian renin production. J Med 1989;68:257-268
20. Morris JC, Cole M, Banker BQ, Wright D. Hereditary dysphasic dementia and the Pick-Alzheimer's spectrum. Ann Neurol 1984;16:455-466
21. Williamson K, Sima A, Curry B, Ludwin S. Neuroaxonal dystrophy in young adults: a clinicopathological study of two unrelated cases. Ann Neurol 1982;11:335-343
22. Schindler D, Bishop DF, Wolfe DE, et al. Neuroaxonal dystrophy due to lysosomal alpha-N-acetylgalactosaminidase deficiency. N Engl J Med 1989;320:1735-1740
23. Wang AM, Schindler D, Desnick RJ. Schindlet disease: the molecular lesion in the α-N-acetylgalactosaminidase gene that causes an infantile neuroaxonal dystrophy. J Clin Invest 1990; 86:1752-1756
24. Schmidt RE, Dorsey D, Parvin CA, et al. Dystrophic axonal swelling develop as a function of age and diabetes in human dorsal root ganglia. J Neuropathol Exp Neurol 1997;56:1028-1043
25. Hayashi S, Akasaki Y, Morimura Y, et al. An autopsy case of late infantile and juvenile neuroaxonal dystrophy with diffuse Lewy bodies and neurofibrillary tangles. Clin Neuropathol 1992;11:1-5
26. Yoshikawa H, Tatui S, Hashimoto PH. Diminished retrograde transport causes axonal dystrophy in the nucleus gracilis: electron and light microscopic study. Acta Neuropathol (Berl) 1985;68:93-100
27. Moretto G, Sparaco M, Monaco S, et al. Cytoskeletal changes and ubiquitin expression in dystrophic axons of Seirelberger's disease. Clin Neuropathol 1993;12:34-37
28. Greenberg SG, Davies P, Schein JD, Binder LI. Hydrofluoric acid-treated τ PHF proteins display the same biochemical properties as normal τ. J Biol Chem 1992;267:564-569
29. Hasegawa M, Morisima-Kawashima M, Takio K, et al. Protein sequence and mass spectrometric analysis of tau in the Alzheimer's disease brain. J Biol Chem 1992;267:17047-17054
30. Mercken M, Vandermeeren M, Lubke U, et al. Monoclonal antibodies with selective specificity for Alzheimer tau are directed against phosphatase-sensitive epitopes. Acta Neuropathol 1992;84:265-272
31. Eble AS, Thorpe SR, Baynes JW. Non-enzymatic glycosylation and glucose-dependent cross-linking of protein. J Biol Chem 1983;258:9406-9412
32. Brownlee M, Cerami A, Vlassara H. Advanced glycosylation end products in tissues and the biochemical basis of diabetic complications. N Engl J Med 1988;318:1315-1321
33. Monnier VM, Cerami A. Non enzymatic browning in vivo: possible process for aging of long-lived proteins. Science 1981; 211:491-493
34. Sell DR, Monnier VM. Structural elucidation of a senescence cross-link from human extracellular matrix. J Biol Chem 1989; 264:21597-21602
35. Ledesma MD, Bonay P, Colaco C, Avila J. Analysis of microtubule-associated protein tau glycation in paired-helical filaments. J Biol Chem 1994;269:21614-21619
36. Ledesma MD, Bonay P, Avila J. Tau protein from Alzheimer's disease patients is glycated at its tubulin-binding domain. J Neurochem 1995;65:1658-1664
37. Smith MA, Taneda S, Richey PL, et al. Advanced maillard reaction end products are associated with Alzheimer's disease pathology. Proc Natl Acad Sci USA 1994;91:5710-5714
38. Smith MA, Sayre LM, Monnier VM, Perry G. Oxidative post-translational modifications in Alzheimer's disease. A possible pathogenic role in the formation of senile plaques and neurofibrillary tangles. Mol Chem Neuropathol 1996;28:4l-48
39. Smith MA, Tabaton M, Perry G. Early contribution of oxidative glycation in Alzheimer's disease. Neurosci Lett 1996;217: 210-211
40. Vitek MP, Bhattacharya K, Glendening JM, et al. Advanced glycation end products contribute to amyloidosis in Alzheimer's disease. Proc Natl Acad Sci USA 1994;91:4766-4770
41. Yan S-D, Chen X, Schmidt AM, et al. Glycated tau protein in Alzheimer's disease: a mechanism for induction of oxidant stress. Proc Natl Acad Sci USA 1994;91:7787-7791
42. Chin S, Goldman JE. Glial inclusions in CNS degenerative diseases. J Neuropathol Exp Neurol 1996;55:499-508
43. Bergeron C, Pollanen MS, Weyer MLT, Lang AE. Cortical de-generation in progressive supranuclear palsy. A comparison with cortical-basal ganglionic degeneration. J Neuropathol Exp Neurol 1997;56:726-734
44. Schneider JA, Watts RL, Gearing M, et al. Corticobasal degeneration: neuropathologic and clinical heterogeneity. Neurology 1997;48:959-969
45. Uchihara T, Mitani K, Mori H, et al. Abnormal cytoskeletal pathology peculiar to corticobasal degeneration is different from that of Alzheimer's disease or progressive supranuclear palsy. Acta Neuropathol 1994;88:379-383
46. Feany MB, Ksiezak-Reding H, Liu WK, et al. Epitope expression and hyperphosphorylation of tau protein in corticobasal degeneration: differentiation from progressive supranuclear palsy. Acta Neuropathol 1995;90:37-43
47. Spillantini MG, Goedert M, Crowther RA, et al. Familial multiple system tauopathy with presenile dementia: a disease with abundant neuronal and glial tau filaments. Proc Natl Acad Sci USA 1997;94:4113-4118